Polymer Capital Management HK LTD Invests $3 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Polymer Capital Management HK LTD purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 36,800 shares of the biotechnology company’s stock, valued at approximately $3,000,000.

A number of other hedge funds have also recently added to or reduced their stakes in ARWR. Versant Capital Management Inc raised its position in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its position in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. Optiver Holding B.V. lifted its stake in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in Arrowhead Pharmaceuticals in the second quarter valued at approximately $39,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $87.11 on Monday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.44 and a twelve month high of $95.49. The firm has a fifty day simple moving average of $82.84 and a 200 day simple moving average of $72.87. The company has a market capitalization of $12.27 billion, a PE ratio of -38.72 and a beta of 1.27. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. During the same period last year, the company posted ($1.26) EPS. The business’s revenue was up 171.0% compared to the same quarter last year. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 11,600 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ARWR. Piper Sandler reiterated an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price on the stock. Royal Bank Of Canada upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Leerink Partners raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday, June 17th. Finally, HC Wainwright boosted their price objective on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.